IMTXW

Immatics N.V. Warrants
IMTXW

Delisted

IMTXW was delisted on the 30th of June, 2025.

Back to rankings
 

About: Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Employees: 423

Healthcare Biotechnology
Charts implemented using Lightweight Charts™